Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2025-07-17 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
募集资金管理制度
Regulatory Filings Classification · 95% confidence The document is titled as "募集资金管理制度" which translates to "Fundraising Capital Management System" and details the internal management rules and procedures for the use and supervision of funds raised by the company through stock issuance and other financing activities. It includes sections on the storage, usage, changes in use, and supervision of raised funds, as well as responsibilities and legal compliance. The document is a formal announcement of the company's internal policy regarding fundraising capital management, approved by the board and pending shareholder approval. It does not contain financial statements, earnings data, or audit results, nor is it a report of voting results or a call transcript. It is not a report publication announcement since it contains substantive content rather than just announcing a report. The document is best classified as a Regulatory Filing (RNS) because it is a regulatory disclosure of internal management rules related to fundraising capital, which does not fit into more specific categories like capital/financing update (CAP) or governance information (CGR) since it focuses specifically on fundraising capital management rules rather than general governance or financing events.
2025-07-17 Chinese
董事会提名委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the 'Board of Directors Nomination Committee Working Rules' of Beijing Xinghao Pharmaceutical Co., Ltd. It details the structure, responsibilities, procedures, and rules of the board nomination committee. There is no financial data, no mention of financial results, no shareholder voting results, no legal proceedings, no capital changes, no earnings information, and no report publication announcement. The content focuses on governance structure and internal board committee rules, which aligns with governance information filings. The document length is 3171 characters, which is relatively short but contains substantive governance content, not just an announcement or summary. Therefore, the most appropriate classification is Governance Information (CGR).
2025-07-17 Chinese
董事及高级管理人员薪酬管理制度
Remuneration Information Classification · 95% confidence The document is a detailed internal policy regarding the remuneration management system for the company's directors and senior management personnel. It includes sections on principles, management structure, salary standards, adjustments, and related governance. It is not a financial report, earnings release, or announcement of voting results. It is a governance-related document focused on compensation rules and procedures for board members and executives. Therefore, it fits the category of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors. The document length and content confirm it is the actual policy, not just an announcement or summary.
2025-07-17 Chinese
利润分配管理制度
Regulatory Filings Classification · 95% confidence The document is titled as a 'Profit Distribution Management System' issued by the company's board, detailing internal policies and procedures for profit distribution, dividend policy, and related governance. It includes sections on decision-making, principles, supervision, and disclosure related to profit distribution. The document is a formal announcement of a corporate governance policy rather than a financial report or earnings release. It is not a report of voting results, nor a proxy solicitation, nor a remuneration report. It is a regulatory announcement about internal management rules concerning profit distribution. Given the nature and length (2540 characters), it is not a full annual or interim report, nor an earnings release. It fits best under Regulatory Filings (RNS) as a general regulatory announcement of internal management system changes and policies.
2025-07-17 Chinese
对外投资管理制度
Governance Information Classification · 95% confidence The document is titled as "北京星昊医药股份有限公司对外投资管理制度" which translates to "Beijing Xinghao Pharmaceutical Co., Ltd. External Investment Management System." It is a detailed internal management system document outlining the company's policies, procedures, and governance related to external investments. It includes sections on approval authority, organizational structure, investment management, personnel management, financial management, auditing, and information disclosure. The document is not a financial report, earnings release, or announcement of voting results. It is a governance-related document detailing internal rules and management practices. Therefore, it fits best under the category of Governance Information (CGR). The document length (6485 characters) and content confirm it is a full policy document, not a brief announcement or certification.
2025-07-17 Chinese
董事会战略委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the 'Board of Directors Strategic Committee Working Rules' of Beijing Xinghao Pharmaceutical Co., Ltd. It details the composition, responsibilities, decision-making procedures, meeting rules, and other governance-related aspects of the Board's Strategic Committee. There is no financial data, no mention of financial results, no shareholder voting results, no capital changes, no legal proceedings, and no report publication announcements. The document is a governance-related internal regulation or guideline issued by the Board. Therefore, it fits best under the category of Governance Information (CGR). The document length is 2860 characters, which is relatively short but contains substantive governance content, not just an announcement or notice. Hence, the classification is CGR with high confidence.
2025-07-17 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.